Scarica l'app Stockscreener
2.39
4.82%
0.11
Precedente Chiudi:
$2.28
Aprire:
$2.22
Volume 24 ore:
193.35K
Relative Volume:
2.22
Capitalizzazione di mercato:
$112.59M
Reddito:
$18.11M
Utile/perdita netta:
$-18.95M
Rapporto P/E:
-5.4629
EPS:
-0.4375
Flusso di cassa netto:
-
1 W Prestazione:
+41.42%
1M Prestazione:
+27.81%
6M Prestazione:
+16.02%
1 anno Prestazione:
-11.81%
Intervallo 1D:
$2.22
$2.55
Intervallo di 1 settimana:
$1.80
$2.55
Portata 52W:
$1.325
$3.5807
Adagene Inc Adr Stock (ADAG) Company Profile
Confronta ADAG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
2.39 | 92.33M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Iniziato | Leerink Partners | Outperform |
| 2025-01-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Iniziato | China Renaissance | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | Jefferies | Buy |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Adagene Inc Adr Borsa (ADAG) Ultime notizie
What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
HC Wainwright Issues Pessimistic Forecast for Adagene (NASDAQ:ADAG) Stock Price - Defense World
How to read the order book for Adagene Inc. Depositary Receipt2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Q3 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
H.C. Wainwright lowers Adagene stock price target to $7 on development path clarity - Investing.com
Adagene's 22.4% Surge: Clinical Breakthroughs and Strategic Alliances Ignite Biotech Volatility - AInvest
How institutional ownership impacts Adagene Inc. Depositary Receipt stockPortfolio Gains Report & Risk Controlled Daily Plans - Newser
What indicators show strength in Adagene Inc. Depositary ReceiptJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser
Published on: 2025-08-12 20:31:18 - Newser
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Cancer Drug Breakthrough: Adagene's ADG126 Doubles Standard Survival Rate as Sanofi Backs Development - Stock Titan
Is Adagene Inc. Depositary Receipt still worth holding after the dipFree Low Risk Picks for Daily Trading - Newser
Why Adagene Inc. Depositary Receipt is moving todayStock Price Prediction Using AI Tools - Newser
Q2 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
Using R and stats models for Adagene Inc. Depositary Receipt forecastingFree AI Forecast for Trending Stocks - Newser
Adagene (NASDAQ:ADAG) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Leerink Partners Begins Coverage on Adagene (NASDAQ:ADAG) - Defense World
Leerink Partners initiates Adagene stock with Outperform rating on cancer drug potential - Investing.com India
What are analysts’ price targets for Adagene Inc. Depositary Receipt in the next 12 monthsAccelerated investment success - Jammu Links News
Why did ADAG's Q4 2020 EPS miss forecasts drastically? - AInvest
Published on: 2025-07-28 00:29:47 - jammulinksnews.com
Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest
Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire
Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic By Stocktwits - Investing.com India
Adagene advances muzastotug to phase 2 trial after FDA meeting By Investing.com - Investing.com South Africa
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA - MarketScreener
Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting - TipRanks
Adagene advances muzastotug to phase 2 trial after FDA meeting - Investing.com
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewswire
Adagene's Cancer Drug Shows Breakthrough 29% Response Rate, FDA Fast-Tracks Phase 2 Trial - Stock Titan
Adagene Inc. and ConjugateBio Inc. Partner to Develop Novel Antibody Drug Conjugate - MarketScreener
Adagene to provide antibody to ConjugateBio for bispecific ADC development By Investing.com - Investing.com South Africa
Adagene Partners With ConjugateBio to Develop ADC Programs - MarketScreener
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewswire
Adagene to provide antibody to ConjugateBio for bispecific ADC development - Investing.com
Adagene Enters $30B ADC Market Through Strategic ConjugateBio Partnership for Novel Cancer Therapeutics - Stock Titan
Adagene Secures $25 Million Investment from Sanofi to Advance Cancer Therapies - TipRanks
Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewswire
Sanofi invests up to $25 million in Adagene, exercises third option By Investing.com - Investing.com
Adagene (NASDAQ:ADAG) Trading 0.3% Higher – Here’s Why - Defense World
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times
Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq
Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan
Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World
Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene Inc Adr Azioni (ADAG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):